A Clinical Trial on Hepatitis B Vaccine Activated-Dendritic Cells Combined With Anti-HBV Drugs in CHB
Status:
Unknown status
Trial end date:
2018-11-01
Target enrollment:
Participant gender:
Summary
The anti-virus effects is not satisfying in some of Chronic Hepatitis B（CHB) patients who
have been on anti-Hepatitis B Virus (HBV) drugs therapy. Dendritic cell (DC) is critical in
Hepatitis B Virus (HBV) specific immunity in the process of producing HBV promoter specific
cytotoxic T cells (CTLs) and specific T helper cells (HTLs), however they are defective in
CHB patients. Therefore, if it were going to remove HBV completely, it mainly depends if the
body itself can produce enough HBV specific cytotoxic T cells (CTLs) and specific T helper
cells (HTLs). Our research is to plus Hepatitis B Vaccine Activated-DCs therapy to CHB
patients who have been on anti-HBV drugs but with poor effects, supposing to significantly
improve anti-HBV efficacy, even to clean HBV from the patients.